US · Healthcare · Biotechnology
EPS came in at -0.12 against a street estimate of -0.14 — a beat of 14.3%.
Analysts rate Nautilus Biotechnology Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $4.00.
CONFIDENT Nautilus is concentrating on proteoforms, reporting early commercial traction and strong assay reproducibility, while targeting a 2027 platform launch and considering additional funding. Q3 FY26 Analysts focused on SEEDS economics, AI data opportunities, commercial demand, launch readiness and early-access traction. Management emphasized milestone-based execution, growing tau interest and a measured 2027 rollout. 2026-10-27…
Full summary in the app.
| Fund | Stake |
|---|---|
| Perceptive Advisors LLC | 9.13% |
| Cercano Management LLC | 5.63% |
| BlackRock Inc | 2.11% |
| Vanguard Capital Management, LLC | 2.00% |
| Comprehensive Financial Management LLC | 1.73% |
| Citadel Advisors Llc | 1.49% |
| Geode Capital Management, LLC | 0.99% |
| Acadian Asset Management LLC | 0.83% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nautilus Biotechnology Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.